Advertisement
Australia markets close in 9 minutes
  • ALL ORDS

    7,838.30
    -99.20 (-1.25%)
     
  • ASX 200

    7,577.40
    -105.60 (-1.37%)
     
  • AUD/USD

    0.6540
    +0.0017 (+0.26%)
     
  • OIL

    84.04
    +0.47 (+0.56%)
     
  • GOLD

    2,350.10
    +7.60 (+0.32%)
     
  • Bitcoin AUD

    98,707.13
    +504.23 (+0.51%)
     
  • CMC Crypto 200

    1,389.16
    -7.38 (-0.53%)
     
  • AUD/EUR

    0.6095
    +0.0022 (+0.37%)
     
  • AUD/NZD

    1.0964
    +0.0007 (+0.06%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,701.16
    +416.62 (+2.41%)
     
  • NIKKEI 225

    37,951.06
    +322.58 (+0.86%)
     

Why Shares of uniQure Rose 14.61% on Wednesday

Why Shares of uniQure Rose 14.61% on Wednesday

Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.